Pre-made Vesencumab benchmark antibody ( Whole mAb, anti-NRP1 therapeutic antibody, Anti-BDCA4/CD304/NP1/NRP/VEGF165R Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-618

Pre-Made Vesencumab biosimilar, Whole mAb, Anti-NRP1 Antibody: Anti-BDCA4/CD304/NP1/NRP/VEGF165R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Roche and Genentech are developing vesencumab, a human IgG1 monoclonal antibody that targets neuropilin 1 (NRP1), for the treatment of solid tumours.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-618-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Vesencumab biosimilar, Whole mAb, Anti-NRP1 Antibody: Anti-BDCA4/CD304/NP1/NRP/VEGF165R therapeutic antibody
INN Name Vesencumab
TargetNRP1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI Structure2qqn:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesGenentech;Roche
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Development Techna